Literature DB >> 35157124

Clinical utility of near-infrared perfusion assessment of the gastric tube during Ivor Lewis esophagectomy.

Elke Van Daele1, Naomi De Bruyne2, Hanne Vanommeslaeghe2, Yves Van Nieuwenhove2, Wim Ceelen2, Piet Pattyn2.   

Abstract

BACKGROUND: Anastomotic leakage (AL) after Ivor Lewis esophagectomy with intrathoracic anastomosis carries a significant morbidity. Adequate perfusion of the gastric tube (GT) is an important predictor of anastomotic integrity. Recently, near infrared fluorescent (NIRF) imaging using indocyanine green (ICG) was introduced in clinical practice to evaluate tissue perfusion. We evaluated the feasibility and efficacy of GT indocyanine green angiography (ICGA) after Ivor Lewis esophagectomy.
METHODS: This retrospective analysis used data from a prospectively kept database of consecutive patients who underwent Ivor Lewis (IL) esophagectomy with GT construction for cancer between January 2016 and December 2020. Relevant outcomes were feasibility, ICGA complications and the impact of ICGA on AL.
RESULTS: 266 consecutive IL patients were identified who matched the inclusion criteria. The 115 patients operated with perioperative ICGA were compared to a control group in whom surgery was performed according to the standard of care. ICGA perfusion assessment was feasible and safe in all 115 procedures and suggested a poorly perfused tip in 56/115 (48.7%) cases, for which additional resection was performed. The overall AL rate was 16% (43/266), with 12% (33/266) needing an endoscopic our surgical intervention and 6% (17/266) needing ICU support. In univariable and multivariable analyses, ICGA was not correlated with the risk of AL (ICGA:14.8% vs non-ICGA:17.2%, p = 0.62). However, poor ICGA perfusion of the GT predicted a higher AL rate, despite additional resection of the tip (ICGA poorly perfused: 19.6% vs ICG well perfused: 10.2%, p = 0.19).
CONCLUSIONS: ICGA is safe and feasible, but did not result in a reduction of AL. The interpretation and necessary action in case of perioperative presence of ischemia on ICGA have yet to be determined. Prospective randomized trials are warranted to analyze its benefit on AL in esophageal surgery. Trial registration Ethical approval for a prospective esophageal surgery database was granted by the Ethical committee of the Ghent University Hospital. Belgian registration number: B670201111232. Ethical approval for this retrospective data analysis was granted by our institutional EC. REGISTRATION NUMBER: BC-09216.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Anastomotic leakage; Esophagectomy; Indocyanine green angiography; Ivor lewis; Near infrared fluorescence imaging; Stomach graft

Mesh:

Substances:

Year:  2022        PMID: 35157124     DOI: 10.1007/s00464-022-09091-3

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   3.453


  36 in total

1.  Preoperative chemoradiotherapy for esophageal or junctional cancer.

Authors:  P van Hagen; M C C M Hulshof; J J B van Lanschot; E W Steyerberg; M I van Berge Henegouwen; B P L Wijnhoven; D J Richel; G A P Nieuwenhuijzen; G A P Hospers; J J Bonenkamp; M A Cuesta; R J B Blaisse; O R C Busch; F J W ten Kate; G-J Creemers; C J A Punt; J T M Plukker; H M W Verheul; E J Spillenaar Bilgen; H van Dekken; M J C van der Sangen; T Rozema; K Biermann; J C Beukema; A H M Piet; C M van Rij; J G Reinders; H W Tilanus; A van der Gaast
Journal:  N Engl J Med       Date:  2012-05-31       Impact factor: 91.245

2.  Intraoperative Doppler assessment of gastric tube perfusion in esophagogastroplasty.

Authors:  Christo Tsekov; Orlin Belyaev; Oleg Tcholakov; Alexander Tcherveniakov
Journal:  J Surg Res       Date:  2005-09-12       Impact factor: 2.192

3.  Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  F Lordick; C Mariette; K Haustermans; R Obermannová; D Arnold
Journal:  Ann Oncol       Date:  2016-09       Impact factor: 32.976

4.  Benchmarking Complications Associated with Esophagectomy.

Authors:  Donald E Low; Madhan Kumar Kuppusamy; Derek Alderson; Ivan Cecconello; Andrew C Chang; Gail Darling; Andrew Davies; Xavier Benoit D'Journo; Suzanne S Gisbertz; S Michael Griffin; Richard Hardwick; Arnulf Hoelscher; Wayne Hofstetter; Blair Jobe; Yuko Kitagawa; Simon Law; Christophe Mariette; Nick Maynard; Christopher R Morse; Philippe Nafteux; Manuel Pera; C S Pramesh; Sonia Puig; John V Reynolds; Wolfgang Schroeder; Mark Smithers; B P L Wijnhoven
Journal:  Ann Surg       Date:  2019-02       Impact factor: 12.969

5.  Predictors of anastomotic leak after esophagectomy: an analysis of the society of thoracic surgeons general thoracic database.

Authors:  Edmund S Kassis; Andrzej S Kosinski; Patrick Ross; Katherine E Koppes; James M Donahue; Vincent C Daniel
Journal:  Ann Thorac Surg       Date:  2013-09-24       Impact factor: 4.330

6.  Perfusion of the gastric conduit during esophagectomy.

Authors:  Gustav Linder; Jakob Hedberg; Martin Björck; Magnus Sundbom
Journal:  Dis Esophagus       Date:  2017-01-01       Impact factor: 3.429

7.  Decreased conduit perfusion measured by spectroscopy is associated with anastomotic complications.

Authors:  Thai H Pham; Kyle A Perry; C Kristian Enestvedt; Dan Gareau; James P Dolan; Brett C Sheppard; Steven L Jacques; John G Hunter
Journal:  Ann Thorac Surg       Date:  2011-02       Impact factor: 4.330

8.  Morbidity, mortality, cost, and survival estimates of gastrointestinal anastomotic leaks.

Authors:  Florence E Turrentine; Chaderick E Denlinger; Virginia B Simpson; Robert A Garwood; Stephanie Guerlain; Abhinav Agrawal; Charles M Friel; Damien J LaPar; George J Stukenborg; R Scott Jones
Journal:  J Am Coll Surg       Date:  2014-11-08       Impact factor: 6.113

9.  Defining Benchmarks for Transthoracic Esophagectomy: A Multicenter Analysis of Total Minimally Invasive Esophagectomy in Low Risk Patients.

Authors:  Henner M Schmidt; Susanne S Gisbertz; Johnny Moons; Ioannis Rouvelas; Juha Kauppi; Andrew Brown; Emanuele Asti; Misha Luyer; Sjoerd M Lagarde; Felix Berlth; Annouck Philippron; Christiane Bruns; Arnulf Hölscher; Paul M Schneider; Dimitri A Raptis; Mark I van Berge Henegouwen; Philippe Nafteux; Magnus Nilsson; Jari Räsanen; Francesco Palazzo; Ernest Rosato; Stuart Mercer; Luigi Bonavina; Grard Nieuwenhuijzen; Bas P L Wijnhoven; Wolfgang Schröder; Piet Pattyn; Peter P Grimminger; Christian A Gutschow
Journal:  Ann Surg       Date:  2017-11       Impact factor: 12.969

10.  Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.

Authors:  Joel Shapiro; J Jan B van Lanschot; Maarten C C M Hulshof; Pieter van Hagen; Mark I van Berge Henegouwen; Bas P L Wijnhoven; Hanneke W M van Laarhoven; Grard A P Nieuwenhuijzen; Geke A P Hospers; Johannes J Bonenkamp; Miguel A Cuesta; Reinoud J B Blaisse; Olivier R C Busch; Fiebo J W Ten Kate; Geert-Jan M Creemers; Cornelis J A Punt; John Th M Plukker; Henk M W Verheul; Ernst J Spillenaar Bilgen; Herman van Dekken; Maurice J C van der Sangen; Tom Rozema; Katharina Biermann; Jannet C Beukema; Anna H M Piet; Caroline M van Rij; Janny G Reinders; Hugo W Tilanus; Ewout W Steyerberg; Ate van der Gaast
Journal:  Lancet Oncol       Date:  2015-08-05       Impact factor: 41.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.